All In Biotech

Drug Trial Radar · NCT03808870

A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Asian Patients With Advanced Cancer

A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Efficacy of NBM-BMX in Asian Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

Dec 28, 2018

Primary completion

Feb 12, 2022

Study completion Feb 16, 2022

Sponsor

Sponsor type
Industry
First posted
Jan 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

NBM-BMX is an orally available new chemical entity to inhibit HDAC8 activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. The objectives of this study are to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors (Arm A) or in combination with the standard of care treatment (i.e., concomitant RT/TMZ followed by adjuvant TMZ) in subjects with newly diagnosed glioblastoma (Arm B).

Conditions

  • Malignant Neoplasm

Interventions

  • NBM-BMX softgel capsulesDrug

    Patients will initially receive NBM-BMX orally once a day at 100 mg per day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT) of NBM-BMX [Safety and Tolerability]Time frame: up to 28 days
  2. Maximum tolerated dose (MTD) of NBM-BMX [Safety and Tolerability]Time frame: up to 28 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.